cemiplimab
sanofi,regeneron
['cemiplimab', 'congrat']
another day at #esmo22 another win for neoadjuvant immunotherapy. this time with stage ii-iv cutaneous scc. neoadjuvant cemiplimab induces 50.6% pathcr, 63.3% combined path response. co-published congrats 
#Melanoma medical oncologist and #immunotherapy & drug development investigator at @MDAndersonNews. Co-Director of the #BrainMets Clinic. Views are my own.